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Summary
 
The T cell receptor (TCR), from a xeno-reactive murine cytotoxic T lymphocyte clone
AHIII12.2, recognizes murine H-2D
 
b
 
 complexed with peptide p1027 (FAPGVFPYM), as well
as human HLA-A2.1 complexed with peptide p1049 (ALWGFFPVL). A commonly proposed
model (the molecular mimicry model) used to explain TCR cross-reactivity suggests that the
molecular surfaces of the recognized complexes are similar in shape, charge, or both, in spite of
the primary sequence differences. To examine the mechanism of xeno-reactivity of AHIII12.2,
we have determined the crystal structures of A2/p1049 and D
 
b
 
/p1027 to 2.5 Å and 2.8 Å res-
olution, respectively. The crystal structures show that the TCR footprint regions of the two
class I complexes are significantly different in shape and charge. We propose that rather than
simple molecular mimicry, unpredictable arrays of common and differential contacts on the
two class I complexes are used for their recognition by the same TCR.
Key words: major histocompatibility complex • crystallography • xeno-reactivity • 
transplantation • T cell receptor
 
T
 
he TCR, expressed on the surface of CD8
 
1
 
 CTL, rec-
ognizes specific class I MHC/peptide complexes on
APC. The result of the recognition is typically lysis of the
APC. The mature class I molecule is a ternary complex
containing a glycoprotein heavy chain, a noncovalently as-
sociated light chain 
 
b
 
2
 
-microglobulin (
 
b
 
2
 
m),
 
1
 
 and a small
antigenic peptide (typically 8–10 residues). Crystal struc-
tures of class I/peptide complexes reveal that the peptide-
binding region of class I is a cleft formed by two 
 
a
 
 helices
in the 
 
a
 
1 and 
 
a
 
2 domains of the heavy chain (for review
see reference 1). Each specific class I molecule binds a large
set of peptides through the interaction between the peptide
termini and conserved residues in MHC (2, 3). The pep-
tides bound to a specific class I allotype share two or more
relatively invariant residues (the anchor residues). The an-
chor residues bind in specific pockets generated by the
polymorphic residues in the class I heavy chain (2, 4, 5).
The peptide terminal residues and the anchor residues have
a predictable orientation, whereas other residues in each
peptide usually have unique main chain conformations and
side chain orientations corresponding to their specific se-
quences (3). As yet, there is not a set of rules to predict the
conformation of a peptide based on its sequence and the
class I allotype to which it binds.
Recent crystallographic studies of TCR/class I com-
plexes (A6/HLA-A2/Tax, B7/HLA-A2/Tax, 2C/H-2K
 
b
 
/
dEV8, and N15/H-2K
 
b
 
/VSV8) (6–9) reveal a similar, diag-
onal orientation of the TCR over the peptide-binding cleft
of each class I/peptide complex. The complementarity de-
termining region (CDR) loops from each TCR (with the
exception of CDR2
 
b
 
 in A6 and CDR1
 
b
 
 in B7) make
contacts with both the peptide and the 
 
a
 
1 and 
 
a
 
2 helices
of class I molecule, although the individual residues that are
in contact with the CDRs are different in each class I.
There are significant numbers of interactions between con-
served class I residues and TCR, leading to the proposition
that the orientation of TCR observed in these crystal struc-
tures is a general feature of most TCR/class I complexes.
The conformation of the class I molecule remains the same
both before and after TCR binding (6–9), although the
center of the Tax peptide adjusts its conformation upon
TCR binding in the A6/HLA-A2/Tax and B7/HLA-A2/
Tax structures. Conversely, the peptide retains the same
conformation in the 2C/H2-K
 
b
 
/dEV8 structure (except
for one side chain reorientation), but the CDR loops of the
TCR (especially CDR1 and CDR3 in the 
 
a
 
 subunit) show
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2
 
m, 
 
b
 
2
 
-microglobulin; CDR, comple-
mentarity determining region. 
360
 
T Cell Xeno-reactivity in the Absence of Molecular Mimicry
 
large shifts relative to their positions in the structure of the
uncomplexed 2C TCR. A similar comparison cannot be
made for A6 and B7 because the unliganded structures are
not known.
Although a TCR may often appear to be highly specific
for a given cognate ligand, there are numerous examples in
the literature of T cell cross-reactivity (10). Cross-recog-
nized ligands can consist of different peptides presented by
the same class I molecule, the same peptide presented by
different class I allotypes, or distinct class I/peptide com-
plexes. The ability of a single TCR to engage different but
related ligands, either optimally or suboptimally, is pro-
posed to play an important role in many immune processes
(11–13).
Biochemical and molecular biological studies have been
conducted to characterize the molecular basis for T cell
cross-reactivity. The most popular model proposed from
these studies is the molecular mimicry model, where differ-
ent class I/peptide complexes form similar (spatially equiva-
lent) antigenic surfaces in shape, charge, or both (14, 15). A
recent paper (16) suggests a modified molecular mimicry
model, in which a critical local charge mimicry formed by
two residues contribute to the recognition of syngeneic and
allogeneic class I/peptide complexes by the same TCR.
Cross-reactivity of TCR for different MHC allotypes
within the same species is termed allo-reactivity, and cross-
reactivity for MHC across species is termed xeno-reactiv-
ity. Xeno-reactivity requires the pairing of incompatible
class I and CD8 molecules as well as the participation of in-
compatible costimulatory molecules for activation, and as
such is more complicated than allo-reactivity. However, at
the level of TCR and class I/peptide binding, xeno-reac-
tivity can be viewed as an extreme case of T cell allo- or
cross-reactivity. The study of a xeno-reactive system may
reveal a more general mechanism which covers the whole
scope of T cell cross-reactivity.
The CD8
 
1
 
 CTL clone AHIII12.2 was derived from a
C57BL/6 (H-2b) mouse injected with the human lympho-
blastoid cell line JY (17). It engages in peptide-specific xeno-
recognition of the human class I molecule HLA-A
 
*
 
0201
(designated A2) complexed with the peptide ALWGFFPVL
(designated p1049). AHIII12.2 also recognizes murine class I
H-2D
 
b
 
 (designated D
 
b
 
) complexed with the synthetic pep-
tide FAPGFFPYL (designated p1058) and closely related
analogues (18). The sequences of both the peptides and class
I molecules are significantly different between these two
complexes. Nevertheless, they are both recognized by a
single TCR. Experiments done using singly substituted
peptides indicate that the TCR cross-recognition of these
ligands cannot be explained simply by a common motif de-
fined at the level of the peptide (18).
Mutagenesis studies, although powerful, sometimes are
difficult to interpret and are unable to provide a complete
picture of the biological events involved. Therefore, we
have engaged in the present study, and have determined
the crystal structures of A2/p1049 and D
 
b
 
 complexed with
p1027 (FAPGVFPYM) to 2.5 Å and 2.8 Å resolution, re-
spectively. p1027 is a disubstituted analogue of p1058 and
 
is an equally good agonist towards AHIII12.2 (data not
shown). We chose p1027 rather than p1058 for the crystal-
lographic study to maximize the primary sequence differ-
ences between the two class I/peptide complexes so that
we can examine the extreme scope of T cell cross-reactiv-
ity. D
 
b
 
/p1027 describes crystallographically how class I
binds a peptide containing a noncanonical residue at an an-
chor position. More importantly, this study reveals, at a
near atomic resolution, the molecular surfaces of two class
I/peptide complexes recognized by the same TCR. A com-
parison of the potential TCR contacting surfaces shows that
these two complexes do not possess obvious similarity. We
propose that TCR binds the same areas of each class I mol-
ecule, utilizing both common and different contact residues
in these areas. It requires that these contacts, although not
identical between the two complexes, generate sufficient
binding affinity between TCR and these complexes to al-
low for further T cell activation. This, rather than a simple
common surface, accounts for the recognition of these two
complexes by the same TCR.
 
Materials and Methods
 
Preparation of A2/p1049 and D
 
b
 
/p1027.
 
The cDNAs for D
 
b
 
and murine 
 
b
 
2
 
m were gifts from Dr. Stanley G. Nathenson (Al-
bert Einstein College of Medicine, New York, NY) (19). A new
construct of D
 
b
 
 was created to make it consistent with the length
of the A2 construct (20). The new construct was generated by
PCR amplifying residues 1–275 and was cloned into plasmid
vector PLM1 (gifts from Dr. G. Verdine at Harvard University,
Cambridge, MA). The protein was expressed in BL21pLysS cells
(Invitrogen Corp.). Due to incorrect primer design, the first Gly
residue of the heavy chain was left out, and three extra residues
(ArgTrpGlu) were added to the COOH terminus of the heavy
chain. The constructs of A2 heavy chain and human 
 
b
 
2
 
m were
identical to those described in Garboczi (20). Large quantities of
A2, D
 
b
 
, human 
 
b
 
2
 
m, and murine 
 
b
 
2
 
m were produced as inclu-
sion bodies and purified as described previously (20).
 
Synthetic Peptides.
 
Peptides used for crystallization were syn-
thesized by the Peptide Synthesis Facility at the University of
North Carolina at Chapel Hill (Chapel Hill, NC) and the Na-
tional Cancer Institute at NIH (Bethesda, MD). All peptides were
purified by reversed-phase HPLC to 
 
.
 
95% purity, and the iden-
tities were confirmed by laser-desorption mass spectroscopy.
 
Crystallization.
 
A2/p1049 and D
 
b
 
/p1027 were folded in vitro
as described in Garboczi (20). The folded complexes were con-
centrated using an Amicon ultrafiltration cell and purified by
HPLC gel filtration chromatography (Biosep-SEC-S2000; Phe-
nomenex). These complexes were further purified on a FPLC
mono Q column (Pharmacia Biotech). Both complexes were
crystallized using the hanging–drop vapor–diffusion method. The
reservoir solution for A2/p1049 contained 12–16% PEG6000 and
6% dioxane in 25 mM MES buffer, pH 6.5. The hanging drop for
A2/p1049 was a 1:1 mixture of the reservoir solution and 10 mg/
ml protein in 25 mM MES, pH 6.5. The reservoir solution for
D
 
b
 
/p1027 contained 25% PEG8000, 150 mM NaCl, 0.8 M Gly,
and 6% DMSO in 25 mM MES buffer, pH 6.5. The hanging drop
was a 1:1 mixture of the reservoir solution and the protein solu-
tion which contained 10 mg/ml protein and 0.8 M Gly in 25 mM
MES buffer, pH 6.5. Microseeding was necessary for both com-
plexes to obtain crystals suitable for crystallographic studies. 
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Table I.
 
Summary of Crystallographic Analysis
 
Parameters A2/p1049 D
 
b
 
/p1027
Space group P1 C2
Cell dimensions a 
 
5
 
 50.09 Å a 
 
5
 
 91.35 Å
b 
 
5
 
 62.89 Å b 
 
5
 
 109.19 Å
c 
 
5
 
 74.68 Å c 
 
5
 
 57.78 Å
 
a 5
 
 81.98°
 
a 5
 
 90.00°
 
b
 
 
 
5
 
 76.18°
 
b
 
 
 
5
 
 122.81°
 
g
 
 
 
5
 
 77.86°
 
g
 
 
 
5
 
 90.00°
Molecules/asymmetric unit 2 1
Resolution (Å) 2.5 2.8
Number of crystals 1 1
 
R
 
merge
 
 (%)
 
*
 
8.3 (17.6)
 
§
 
9.1 (29.2)
I/
 
s
 
16.6 (6.5) 20.4 (5.9)
Unique reflections 29804 11820
Total observations 77499 62278
Completeness (%) 90.9 (70.8) 99.9 (100.0)
Refinement (F 
 
.
 
 0)
Resolution (Å) 30–2.5 30–2.8
 
R
 
work 
 
(%)
 
‡
 
 (No. of reflections) 25.5 (25716) 25.2 (11200)
 
R
 
free 
 
(%) (No. of reflections) 30.4 (1363) 31.9 (559)
No. of nonhydrogen
protein atoms 6320 3147
No. of water 50 5
Average B factor 37.06 34.39
R.m.s. deviations from ideality
Bonds (Å) 0.007 0.007
Angles (°) 1.905 1.786
Dihedrals (°) 24.466 25.550
Impropers (°) 1.105 1.307
Residues in Ramanchandran
plot (%)
Most favored 90.1 89.3
Additional allowed 9.6 10.1
Generously allowed 0.3 0.6
Disallowed 0.0 0.0
 
*
 
R
 
merge
 
 
 
5
 
 
 
S
 
h
 
S
 
i
 
|
 
I
 
hi
 
-
 
,
 
I
 
.
 
|/
 
S
 
h
 
S
 
i
 
I
 
hi
 
, where 
 
I
 
hi
 
 is the observed intensity
for each reflection h, and 
 
,
 
I
 
.
 
 is the average intensity of multiple ob-
servations of reflection h.
 
§
 
Number in parentheses refers to the highest resolution shell (2.59–2.50 Å
for A2/p1049 and 2.90–2.80 Å for D
 
b
 
/p1027) unless otherwise stated.
 
‡
 
R
 
 
 
5
 
 
 
S
 
h 
 
||
 
F
 
obs 
 
|-
 
k
 
|
 
F
 
cal
 
||/
 
S
 
h 
 
|
 
F
 
obs
 
|, where 
 
R
 
free
 
 is calculated for a
randomly chosen 5% of reflections, 
 
R
 
work
 
 is calculated for the remaining
95% of reflections used for structure refinement.
 
Data Collection and Processing.
 
Crystals of A2/p1049 were
stored in 25 mM MES, pH 6.5, containing 20% PEG6000. Crys-
tals of D
 
b
 
/p1027 were stored in 25 mM MES, pH 6.5, containing
30% PEG8000 and 0.8 M Gly. These crystals were transferred di-
rectly into their corresponding storage buffer plus 30% glycerol,
and were immediately placed in the cryo stream (generated by
the Oxford Cryo System, and the temperature was set at 100 K).
 
The diffraction data were collected on Rigaku R-Axis IIC using
Cu K
 
a
 
 radiation.
The diffraction data were processed using the programs Denzo
and Scalepack (21). Data statistics are shown in Table I.
 
Structure Determination.
 
The structures of both complexes
were determined using the Molecular Replacement method with
the CCP4 program suite (22). The complex of HLA-A2 and a
peptide from HIV reverse transcriptase (3) was used as a model
for the structural solution for A2/p1049. H-2D
 
b
 
 complexed with
a peptide (designated NP) from influenza virus (19) was used as
the model for D
 
b
 
/p1027. The orientation and position of these
models were found using the program AMoRe in CCP4. Solvent
flattening was applied to both crystals to improve the quality of
the density. In addition, twofold averaging using the program
DM in the CCP4 suite was applied to improve the density qual-
ity of A2/p1049. Manual model building into the electron den-
sity was performed using the program O (23).
 
Refinement of A2/p1049.
 
Computational refinement was per-
formed using the program X-PLOR version 3.851 (24) and
Refmac in CCP4 (25). The structure was first refined in X-PLOR
using 8–2.5 Å resolution data. Twofold noncrystallographic-
symmetry restraints were applied to the two molecules in the
asymmetric unit of HLA-A2/p1049 crystals with a weight of 300
kcal mol
 
2
 
1
 
 Å
 
2
 
2
 
. Overall isotropic B factor refinement was per-
formed first, then rigid body refinement was carried out using
three domains: 
 
a1/a2, a3, and b2m. Overall anisotropic B factor
refinement slightly improved Rfree values. Cycles of computa-
tional refinement using positional refinement and simulated an-
nealing (26) followed by manual model rebuilding using maps
with coefficients 2fo-fc and fo-fc (after density modification using
DM) were carried out. The X-PLOR refined structure was fur-
ther refined using Refmac with strict noncrystallographic-sym-
metry restraints (see Refmac manual), a bulk solvent correction,
overall anisotropic B factor correction, and individual B factor re-
finement. 50 water molecules were added in the structure using
program ARP (27) in CCP4. The final Rfree and Rwork factors (F .
0) between 30 and 2.5 Å resolution are 30.4 and 25.5%, respec-
tively. The refinement statistics are shown in Table I. The final
real-space correlation coefficient (23) between the refined model
and the DM-modified electron density map with coefficients 2fo-
fc is 0.76. The conformation of the peptide was confirmed by the
following averaged omit map procedure (Fig. 1 A). Masks includ-
ing peptide were generated, but the peptide was omitted from
the refined model to generate the phases for the initial map. Two-
fold averaging, solvent flattening, and histogram matching were
applied with the program DM to generate the final omit map.
Refinement of Db/p1027. Db/p1027 was first refined in
X-PLOR using 8.0–2.6 Å data. Rigid body refinement was per-
formed similarly as in A2/p1049. Applying an overall anisotropic
B factor was critical for the improvement of Rfree and Rwork fac-
tors. Simulated annealing was not helpful for improving the Rfree
in the case of Db/p1027. Rounds of positional refinement and
model rebuilding were carried out. The model rebuilding was
largely based on the electron density maps using 2fo-fc and fo-fc
coefficients. These maps were generated using 30–2.6 Å data al-
though the refinement was only performed for 8–2.6 Å data. The
peptide conformation and other suspicious residues were checked
using omit maps. Omit maps were generated from simulated an-
nealing procedures or by using the randomized omit map proce-
dure described below. The X-PLOR refined structure was fur-
ther refined by Refmac, as in A2/p1049. Individual B factor
refinement significantly improved Rfree. Thus individual B factor
refinement was performed, although the number of parameters362 T Cell Xeno-reactivity in the Absence of Molecular Mimicry
refined was slightly over the number of reflections (Table I). Af-
ter further consideration of the data quality, only data to 2.8 Å
were used for the final round of refinement. The final Rfree and
Rwork factors (F . 0) for Db/p1027 between 30 and 2.8 Å are
31.9 and 25.2%, respectively. The refinement statistics are shown
in Table I. The final real-space correlation coefficient (23) be-
tween the refined model and the solvent-flattened electron den-
sity map with coefficients 2fo-fc is 0.83.
All residues on the a1/a2 helices have clear and unambiguous
densities. The peptide conformation was confirmed by a random-
ized omit map procedure (29) (Fig. 1 B). A random error ,0.25 Å
was added to each of the refined coordinates that did not contain
peptide. These coordinates with the peptide region omitted were
subject to Refmac refinement, and an omit electron density map
with coefficients 2fo-fc was calculated. The omit map clearly in-
dicates the side chain orientations, although the density is broken
for the main chain between peptide residues 4 and 5, as well as
between residues 5 and 6 (Fig. 1 B). Fig. 1 C shows the final
2fo-fc map surrounding the peptide. The only significant densi-
ties (z3s level) in the fo-fc map is a small positive peak near res-
idue P5. This, in combination with the relatively weak main
chain density near residue P5, may indicate some flexibility
around the middle of the peptide.
The coordinates of both complexes have been deposited with
the Protein Data Bank (Brookhaven, NY). Identifiers are 1b0g
and 1bz9 for A2/p1049 and Db/p1027, respectively.
Results and Discussion
Comparison of A2/p1049 and Db/p1027 with Other Class I
MHC/Peptide Complexes. Class I/peptide complexes have
been extensively studied by crystallography. Detailed com-
parisons of class I/peptide structures have been presented
elsewhere (1). Here we chose A2/RT (sequence ILK-
EPVHGV) (3) and Db/NP (sequence ASNENMETM)
(19) for comparison with A2/p1049 and Db/p1027. These
class I/peptide complexes have essentially identical back-
bone structures when individual domains (the a1/a2 su-
perdomain, the a3 domain, and b2m) are superimposed.
There is a relative domain movement of the a3 domain
and b2m with respect to the a1/a2 superdomain when
comparing Db/p1027 with Db/NP, as well as in comparing
Db/p1027 with A2/p1049 (Fig. 2 A). This type of domain
movement has been observed in other class I crystal struc-
tures (2), and it could be an effect of the packing differ-
ences in the different crystal forms of these class I/peptide
complexes.
When superimposing the a1/a2 superdomain (all pep-
tides in this paper are compared by superimposing the a1/
a2 superdomain), the ends of the peptide are essentially su-
perimposable. However, the middle of the peptide (resi-
dues 3–7) has different backbone conformations and side
chain orientations among these class I complexes (Fig. 2,
B–D). This is consistent with earlier observations (3).
Peptide Binding in the Absence of a Canonical Anchor Residue.
Sequence analysis of the peptides eluted from Db com-
plexes shows that Db strongly prefers Asn at P5 and has a
certain degree of preference for Met, Ile, or Leu at P9 (30).
These observations are consistent with the Db/NP crystal
structure (19). Asn at P5 is deeply buried in a polar pocket
defined by GluA9, GlnA70, GlnA97, and TyrA156 (Fig. 3 A),
and forms hydrogen bonds with the last three residues.
(Throughout this paper, we use A, B, and P to represent class
I heavy chain, b2m, and peptide, respectively. GluA9 refers
to residue 9 of heavy chain, which is a Glu.) MetP9 is bur-
ied in a hydrophobic pocket formed by residues PheA116,
TryA123, IleA124, ThrA143, and TrpA147.
p1027 has the preferred anchor residue (Met) at P9, but
it has Val rather than the normal anchor residue (Asn) at
P5. The hydrophobic ValP5 of p1027 does not bind into
Figure 1. The conformation of p1049 and p1027, as confirmed by the
corresponding omit maps. (A) Averaged omit map of peptide p1049
(ALWGFFPVL) contoured at 1s level. The orientation of the peptide is
such that the a1 helix is behind the plane of the paper, the a2 helix is in
front of the paper, and the b-sheet is below the peptide. All figures in-
volving the peptides are oriented this way unless otherwise stated. (B)
Omit map of peptide p1027 (FAPGVFPYM). This randomized omit map
(see Materials and Methods) contoured at 1s shows all of the side chain
orientations and the conformation of most of the main chain of p1027.
(C) 2fo-fc map (contoured at 1s level) around the peptide. In combina-
tion with the fo-fc map, it confirms the conformation of p1027 observed
in the omit map (see Materials and Methods).363 Zhao et al.
the highly polar pocket that accommodates AsnP5 of NP; it
instead points up toward the solvent (Fig. 3 B). PheP6 (the
residue after ValP5) inserts into the peptide binding cleft in-
stead of pointing up as in the Db/NP structure. PheP6
would have clashed sterically with residue TyrA156 if the
tyrosine had remained in the same position as in Db/NP.
In Db/p1027, the phenol ring of TyrA156 swings away by
roughly 558 to make space for PheP6. As a consequence,
PheP6 serves as a new adventitious anchor residue, and is
buried in a hydrophobic pocket formed by residues TrpA73,
Figure 2. Comparison of A2/
p1049 and Db/p1027 with other
class I/peptide complexes. (A)
Comparison of Ca backbone
structure of Db/p1027 (thick
line) and A2/p1049 (thin line).
The a1/a2 peptide-binding su-
perdomain of the two complexes
are superimposed, while the a3
and  b2m show relative domain
movements between the two
complexes. (B) Comparison of
peptide p1049 (yellow) and RT
(ILKEPVHGV, shown in blue).
Residues on RT are labeled. The
termini of the peptides have simi-
lar conformations whereas the
middle of the peptides show sig-
nificant differences. This is also
seen in C and D. (C) Comparison
of peptide p1027 (purple) and NP
(ASNENMETM, shown in yel-
low). Residues on p1027 are la-
beled. (D) Schematic view of side
chain orientations of peptides in
crystal structures of A2/RT (3),
A2/p1049, Db/NP (19), and Db/
p1027. Note that P1, P2, P8, and
P9 are in the same relative orien-
tations, whereas the others are
seemingly random.364 T Cell Xeno-reactivity in the Absence of Molecular Mimicry
LeuA114, PheA116, TrpA133, TrpA147, and the aromatic ring of
TyrA156 (Fig. 3 B). The original polar pocket changes its
shape due to the movement of TyrA156 (Fig. 3, A and B).
Db/p1027 is the only crystal structure determined to date
of a class I with a peptide that does not have the normal an-
chor residues. What we have observed in the structure of
Db/p1027 may be a general phenomenon. Other class I al-
lotypes also occasionally bind peptides without primary an-
chor residues (31, 32). These peptides must also have com-
pensated for the lost binding energy by using other residues
within the peptide.
Comparison of TCR Contacting Regions in A2/p1049 and
Db/p1027. Several lines of evidence suggest that TCR
docks on a common area and in a similar orientation on
different class I/peptide complexes. In the four cocrystal
structures of TCR/class I (6–9), the TCR is situated diago-
nally across the peptide-binding cleft with the TCR foot-
print centered on the peptide. The a subunit of TCR is lo-
cated close to the NH2 terminus of the peptide, while the
b subunit is close to the COOH terminus of the peptide.
Several contacts at the periphery of the TCR/class I inter-
face involve conserved residues, which may help steer
TCR into a general orientation. Recently, Smith and Lutz
made exhaustive mutations on the a1 and a2 domains of
class I molecule HLA-B7 and tested the recognition of
these mutated molecules by 12 allospecific CTL clones.
They concluded that the 12 CTL clones recognize a dis-
crete surface with the bound peptide in the center. Al-
though the boundaries of the TCR footprints from the 12
clones are not identical, they overlap largely.
Based on the crystal structure of A6/HLA-A2/Tax (6),
the footprint of TCR can be approximated as a rectangular
box with its width being z22 Å, measured from the Ca
atom of A65 to A157. The length of the rectangular box is
z32 Å, measured from the Ca atom of A170 to P9. The
center of the rectangle is located near peptide residue P4.
These dimensions are consistent with what is observed in
the other TCR/MHC cocrystal structures (7, 8). It is also
consistent with an earlier mutational study that suggests the
TCR footprint is roughly 30 3 20 Å2 (34). This rectangu-
lar box contains the peptide and the majority of the a1/a2
helices. In the following paragraphs, we first compare the
peptide and the a1/a2 helices in A2/p1049 and Db/p1027
at an atomic level. We then examine the shape and charge
comparison of these two TCR footprints on the molecular
surface diagrams.
The termini of p1027 and p1049 are fixed by a set of
conserved hydrogen bonds and by specificity pockets that
are complementary for the anchor residues, and thus they
have similar conformations. The backbones of the first and
last residues in p1049 and p1027 (Fig. 4 A) are essentially
superimposable (rmsd 0.7 Å). The side chains of residues at
the ends of the peptide (P1, P2, P8, and P9) have similar
orientations. However, the average difference between Ca
atoms of the middle residues (from P3 to P7) is 2.6 Å. The
side chains of these middle residues also have different ori-
entations (Fig. 4 A and Fig. 2 D). These differences result
in different solvent accessibility patterns of the two pep-
tides. In p1049, residue PheP5 is the most solvent-exposed
residue (Fig. 4 B). Residues in p1027 are more solvent ac-
cessible than those in p1049, as seen by the much higher
protrusion formed by ValP5. Residue TyrP8 in p1027 is also
significantly exposed to solvent (Fig. 4 B).
In the crystal structures of TCR complexed with A2/
Tax (6) and Kb/dEV8 (8), 16 and 15 residues on their re-
spective a1 and a2 helices were found to be in direct
Figure 3. Anchor binding for
Db/p1027 compared to Db/NP.
(A) Stereo view of binding of
anchor AsnP5 in Db/NP. Peptide
backbone is in black. Db side
chains in green. The Tyr that
changes conformation during
p1027 binding is shown in red.
(B) Binding of adventitious an-
chor PheP6 in Db/p1027. Instead
of the normal anchor residue
Asn at P5, there is a Phe at P6 in
p1027 that is used as an anchor.
Color scheme is as in A.365 Zhao et al.
contact with TCR. These TCR-contacting residues do not
completely overlap between the two crystal structures. Since
we cannot predict which set of residues will be utilized by
Db or A2 to interact with AHIII12.2, we will analyze all
of these potential contacts. Based on the two cocrystal
structures, there are 23 unique residues on A2/p1049 and
Db/p1027 that may interact with the AHIII12.2 TCR. In-
terestingly, these 23 residues include important residues for
all TCR/class I/peptide complexes examined to date (7).
10 of these 23 residues are different between A2 and Db
(Table II and Fig. 5). Except for the conservative change
from Ala to Gly at position A69, all the other changes in-
volve dramatic charge, polarity, or size differences. Among
the 13 residues with common amino-acid identities, some
have taken different conformations between the two com-
plexes (Fig. 5). Most of these common residues are highly
conserved among different human or mouse class I alleles.
For example, residue LysA66 is conserved among 23 differ-
ent HLA-A allotypes, and the remaining 12 residues are
conserved among at least 49 different HLA-A allotypes.
These conserved residues are likely to help dock the TCR
in a common orientation on class I/peptide and contribute
to the binding energy between TCR and class I/peptide.
However, the different residues between these complexes
also have to contribute significantly to the binding energy
in order to differentiate between different antigenic com-
plexes.
In Fig. 6, we placed the putative TCR footprint on the
molecular surfaces of the crystal structures of A2/p1049
and Db/p1027. Dispersed and local similarities exist be-
tween these two complexes, but there are many differ-
ences. The following is a comparison of the two structures
from left to right with respect to Fig. 6.
In Db/p1027, P1 is flanked by a pair of symmetrically lo-
cated positive charges (Fig. 6 A), contributed on the left by
ArgA62 and on the right by LysA66 (Fig. 5 and Table II). In
A2/p1049 A62 is a Gly instead of Arg, so there is no posi-
tive charge at the top left of P1 (Fig. 6 B). In A2/p1049, the
positive patch on the right side of P1 is much larger than in
Db/p1027 because of the presence of ArgA65 in addition to
LysA66. This additional positive charge does not exist in Db/
p1027, because in Db residue A65 is a Gln. Due to the
change of ArgA62 in Db to GlyA62 in A2, residue GluA63 is
exposed and leads to the presence of a negative charge on
the top of P1 in A2/p1049 not seen in Db/p1027. How-
ever, the bottom left area of P1 is much more negatively
charged in Db/p1027 than the area in A2/p1049, due to the
presence of GluA163 in Db, which is a Thr in A2.
P2 (Leu) in p1049 is buried in the HLA-A2 B pocket
(35). P2 in p1027 points in the same direction, but is a
much smaller residue (Ala). Neither makes any apparent
contribution to the molecular surface in either structure.
The position 3 residues (Trp in p1049 and Pro in p1027)
are pointed into pocket D, away from the TCR contact
Figure 4. Comparisons of the
A2/p1049 and Db/p1027 struc-
tures. (A) Comparison of peptide
p1027 (FAPGVFPYM, shown in
purple) and p1049 (ALWGFF-
PVL, shown in yellow). Resi-
dues on p1027 are labeled. Ex-
cept for the first and last residues
between the two peptides, the
rest of the peptides are different.
Note that residues in common
between the two peptides (P6
and P7) are in different confor-
mations. (B) Solvent accessibil-
ity of residues in p1027 (solid
bars) and p1049 (striped bars).
Percentage of solvent exposure is
defined as the ratio of solvent ac-
cessible area in each residue to
the total surface area of the cor-
responding amino acid. P5 is the
most exposed residue in both
peptides.366 T Cell Xeno-reactivity in the Absence of Molecular Mimicry
surface. As can be seen in Fig. 3 C, these residues are al-
most completely buried and, similar to the P2 position, do
not directly contribute to the molecular surface.
The next most prominent difference between the mo-
lecular surfaces is at the center of the peptide at P5. Peptide
residue P5 protrudes higher in Db/p1027 than in A2/
p1049. The reason is obvious when comparing the orienta-
tions of P5 in p1027 and p1049 (Fig. 4 A and Fig. 2 D).
ValP5 in p1027 points up, whereas PheP5 in p1049 mainly
points sideways. This is also consistent with the solvent ac-
cessibility of position P5 in the two peptides (Fig. 4, B and C).
The OE1 atom of GluA70 generates a negative charge above
ValP5 in Db/p1027, but there is no surface charge in A2 be-
cause residue 70 is a His and is buried underneath PheP6.
Positions 6 and 7 are identical in composition (Phe and
Pro, respectively, for both A2/p1049 and Db/p1027) but
very different in orientation between the two complexes
(Fig. 2 D and Fig. 4 A). Although both form hydrophobic
patches, they constitute different topological surfaces to the
right of the P5 protrusion. Position 8 is a Val in A2/p1049
and a Tyr in Db/p1027. These residues are both solvent ex-
posed (Fig. 4 B), but their differing size and chemical na-
ture results in different surface properties in the P8 region
of each complex.
There are similarities between the two molecular sur-
faces at the COOH end of the peptide along the right-
hand border of the TCR footprint, generated by a com-
mon residue LysA146. This highly conserved Lys is located
above and forms a salt bridge with the carboxylate of the
peptide and covers the COOH terminus. A hydrophobic
area surrounds this positive charge at LysA146 in each com-
plex. Close examination shows that the shapes of these hy-
drophobic areas are dissimilar. The depression observed be-
side the left edge of LysA146 in Fig. 6 is much shallower in
Db/p1027 than in A2/p1049, due to three amino-acid
changes. Residues ValP8, AlaA150, and AlaA149 in A2 are the
much larger residues TyrP8, SerA150, and GlnA149 in Db. Ad-
ditionally, the orientation of ProP7 is different between the
two complexes and ProP7 contributes to the shallow de-
pression in Db/p1027.
In summary, there appear to be few similarities in the
TCR contact region of these two complexes when each
area is examined in detail. There is similarity of gross fea-
Table II. Comparison of the 23 Residues on the a1/a2 Helices 
Proposed to Interact with TCR
Residue
number*
Amino acids
in Db/p1027
Amino acids
in A2/p1049
58 Glu Glu
62 Arg Gly
65 Gln Arg
66 Lys Lys
68 Lys Lys
69 Gly Ala
72 Gln Gln
73 Trp Thr
76 Val Val
79 Arg Gly
146 Lys Lys
149 Gln Ala
150 Ser Ala
151 Gly His
154 Glu Glu
155 His Gln
158 Ala Ala
159 Tyr Tyr
162 Gly Gly
163 Glu Thr
166 Glu Glu
167 Trp Trp
170 Arg Arg
*Residues that differ between the complexes are shown in bold.
Figure 5. Comparison of residues on the a helices which potentially contact TCR in Db/p1027 (A) and A2/p1049 (B). There are common residues
(blue) between the two complexes, but significant differences (red) also exist.367 Zhao et al.
tures. The footprint is relatively acidic around P1, hydro-
phobic in the center, and basic around P9. However, these
common features are largely formed by conserved residues
in different class I allotypes. In A2/p1049, the acidic area
around P1 is formed by residues GluA58, GluA61, and
GluA63, and the positive charge around P9 is formed by res-
idue LysA146. Residue A63 is conserved in 40 different
HLA-A allotypes, and residues A58, A61, and A146 are
conserved among 60 different HLA-A allotypes. The hy-
drophobic area in the center is largely formed by hydro-
phobic residues around peptide residue P5. Many peptides
with hydrophobic residues at P5 and P6 do bind to A2
(30). Fig. 6 C shows the potential TCR contacting surface
of a completely unrelated class I/peptide complex (A2/ma-
trix peptide sequence GILGFVFTL) (3). It demonstrates
that these common gross features exist on completely unre-
lated class I/peptide complexes. These features probably
contribute to the binding of TCR in general and are most
Figure 6. Comparison of molecular surfaces of A2/p1049 and Db/p1027. (A) The molecular surface on the TCR contacting region of Db/p1027 with
the electrostatic potential mapped to the surface. This figure was generated using the program Grasp (45). Red and blue colors designate negative and
positive charges, respectively. A, B, C, and D are top views of MHC/peptide complexes with the a1 helix on top of the diagram and the a2 helix on the
bottom of the diagram. The rectangular box is a model TCR footprint derived from the crystal structure of A6/HLA-A2/Tax (6). (B) The molecular
surface of A2/p1049. (C) The molecular surface of A2/matrix. (D) A speculative model of the molecular surface of A2/p1049 after the proposed confor-
mational changes upon the engagement of the AHIII12.2 TCR. Comparison of A, B, and D shows that the TCR contacting surfaces in A2/p1049 and
Db/p1027 have similar features, but significant differences still exist. C indicates the existence of those similar features in a completely unrelated class
I/peptide complex.368 T Cell Xeno-reactivity in the Absence of Molecular Mimicry
likely the features that result in the similar orientation of
TCR on MHC (7, 8). However, they cannot be the sole
contributions, as they would lead to the recognition of
many unrelated A2/peptide complexes by this TCR,
which is obviously not the case.
Potential Conformational Changes of the Peptide. The A6/
HLA-A2/Tax cocrystal structure shows that the Tax pep-
tide changes conformation upon binding by TCR (6).
Comparisons of the molecular surfaces of the A2/p1049
and Db/p1027 complexes should also be evaluated with
respect to potential conformational changes and to the
new molecular surfaces that would be generated by such
changes. Amino acid substitution experiments performed
on A2/p1049 and Db/p1058 can provide us with some in-
formation about the potential conformational changes of
peptide upon TCR binding. The only differences between
p1027 (FAPGVFPYM) and p1058 (FAPGFFPYL) are two
conservative changes at P5 and P9. Leu is a preferred
omega anchor residue for Db bound peptides, but Met is a
readily accepted substitute (30). The hydrophobic PheP5 in
p1058 is not likely to bind in the polar pocket normally de-
signed for AsnP5. It is more likely to be solvent exposed as
is the Val in Db/p1027. Thus, we believe that p1058 binds
to Db in a conformation roughly the same as p1027. The
side chain orientations observed from the structure of Db/
p1027 are consistent with the TCR/MHC interaction data
deduced from the amino acid substitution data generated
previously (18). Therefore, it is likely that p1027 does not
undergo any major conformational change upon TCR
binding to Db/p1027.
The Tax peptide changed conformation in both TCR/
MHC cocrystal structures (6, 7). P6 moved away from the
TCR and P7 moved toward the TCR. Residues P6 and
P7 in p1049 may undergo similar conformational changes
when engaging AHIII12.2. When ProP7 is substituted with
Ala, CTL reactivity is reduced to 40% of the wild-type
level (18). Yet, in the crystal structure, ProP7 points side-
ways toward the a2 helix and is solvent inaccessible. Thus,
it is possible that ProP7 changes conformation and points up
and contacts the TCR upon binding. Accompanying the
change on P7, P6 may move down as observed in Tax. If
this is the case, it will generate a deeper depression sur-
rounding P5 which will make the shape of the hydropho-
bic region surrounding residue P5 (Fig. 6, A and D) similar
to that in Db/p1027, but significant differences (especially
charge distributions) would still exist between the foot-
prints. Furthermore, although P8 in both peptides point up
and are solvent accessible (Fig. 4, A and B), amino acid
substitution experiments demonstrated that P8 in p1058
bound to Db is in contact with TCR, while P8 in p1049
bound to A2 is not (18). These data confirm that the inter-
actions between AHIII12.2 TCR and the two complexes
are different.
Mechanism of T Cell Allo- and Xeno-recognition. The mech-
anism of T cell allo- and xeno-reactivity remains one of the
paradoxes of modern immunology. Through positive and
negative selection, T cells are educated in the thymus to
recognize self-MHC complexed with foreign peptide in
the periphery. The requirements for both MHC and pep-
tide in selection are clear (36). However, even after thymic
education, 1–10% of T cells still recognize allo- or xeno-
MHC antigens that they could not have encountered be-
fore (14, 37). The most popular model proposed to answer
this paradox is that the molecular surfaces of the allo- or
xeno- and syngeneic MHC antigens are similar in shape
or/and charge regardless of their derivation.
The comparison of the TCR contacting surfaces from
the crystal structures shows that A2/p1049 and Db/p1027
are different. These observations suggest that TCR cross-
recognition of these class I/peptide epitopes is not due to
simple shape and/or charge mimicry. Model building ex-
periments on different allo- or cross-reactive class I have
reached similar conclusions (38, 39). These observations,
combined with the amino acid substitution data (18), can
be best interpreted using a functional mimicry model,
where TCR makes contacts with both common and differ-
ent features on the two class I/peptide complexes and the
mimicry is functional instead of structural. The common
features between the two complexes mostly come from
conserved residues and may help to steer TCR into a com-
mon orientation on different class I/peptide complexes.
However, the noncommon features must also contribute
significantly to ensure the specificity of a TCR.
When an allo- or xenogeneic class I interacts with a
TCR, some of the residues under the TCR footprint re-
main the same as in the syngeneic complex, but other resi-
dues, perhaps many, will be different between these com-
plexes. Among those changed residues, some will lose their
interaction with TCR, but others will make adventitious
contacts with TCR. Presumably, the lost and gained inter-
actions will come to a balance, and the overall binding affin-
ity between different class I ligands and TCR will be suffi-
cient to trigger activation of the T cell. The relative
importance of MHC versus peptide in this interaction is not
predicted. There have been reports of peptide-independent
TCR recognition of allo-reactive class I (40). This would
suggest, for that case at least, that the contacts between the
allo-reactive class I and TCR are sufficient to trigger the T
cell, regardless of the peptide bound. Note also that this
model does not suggest that either the TCR or class I has to
be locked into a specific conformation. Loops and side chains
of TCR may move to best accommodate the common and
different contacts on a particular class I/peptide complex.
Recently, Speir et al. (16) generated a model of an allo-
geneic complex (Ld/QL9), based on the crystal structure of Ld
with a mixture of peptides, and compared the model with the
crystal structure of a syngeneic murine class I/peptide com-
plex (Kb/dEV8). Based on these studies, they hypothesized a
modified molecular mimicry model, in which a critical local
charge mimicry (formed by residues SerP7 and AspA77 in Kb/
dEV8 and AspP8 and AsnA77 in Ld/QL9) contributes to the
recognition of these two complexes by the same TCR. The
functional mimicry model proposed here does not rule out
the possibility of this modified molecular mimicry, but we
think the original and modified molecular mimicry model
does not account for all TCR cross-reactivity.369 Zhao et al.
The cocrystal structures of A2/Tax with two different
TCRs (A6 and B7) further demonstrate the requirement
for flexibility in our thoughts about TCR recognition. A6
and B7 recognize A2/Tax by a common docking mecha-
nism, but a different set of residues on the TCR is used to
interact with A2/Tax. Only 1 of the 17 residues on the B7
TCR that contact A2/Tax is also found in the A6/A2/Tax
interface. An additional 12 TCR residues that contact A2/
Tax in the two TCRs are spatially equivalent, but they are
different amino acids. Even when the TCR/MHC interac-
tions were examined at an atomic level, few involved spa-
tially equivalent and identical atoms. Most TCR/MHC in-
teractions are between atomic pairs which are not spatially
equivalent and/or have very different chemical natures.
The sum of these common and different interactions must
have generated sufficient affinity for the same class I to bind
two different TCRs. It is not difficult to imagine that simi-
lar situations can happen between two different class I/pep-
tide complexes with the same TCR.
Crystal structures of several antibody idiotope/antiid-
iotope complexes (41, 42) also demonstrate the absence of
molecular mimicry between the antiidiotope and the anti-
gen. Fields et al. (42) suggested that “the mimicking is
functional, involving similar binding interactions, rather
than exact topological replicas.” For example, 6 out of the
12 hydrogen bonds are structurally (spatially) equivalent,
although residues involved in these hydrogen bonds are
amino acids with different size and chemical natures. We
speculate that in many cases these interactions do not have
to be structurally (or spatially) equivalent (as demonstrated
by the cocrystal structure of TCRs A6 and B7 with A2/
Tax); however, sufficient binding energy between antibody
or TCR with its cross-reactive ligands can still be generated.
The functional mimicry model implies that TCR cross-
reactivity, like antibody cross-reactivity, is unpredictable. It is
possible for cross-reactive ligands to be structurally dissimilar,
yet functionally similar. This mechanism also explains why
the TCR repertoire selected by a single peptide can still rec-
ognize dissimilar ligands (43, 44). The different ligands are
functionally similar with respect to recognition by the TCR.
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